Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
Date:5/2/2013

Pharmaceuticals, Inc.

WCGPhone: 858-436-1400

Phone: 415-946-1076   CADENCE PHARMACEUTICALS, INC.CONDENSED STATEMENTS OF OPERATIONS(unaudited)(in thousands, except per share amounts)Three Months EndedMarch 31,20132012Revenue:Product revenue, net

$
23,612$
8,004Total revenues

23,6128,004Costs and expenses:Cost of product sales

8,1674,246Amortization of patent license

336336Research and development

1,3631,511Selling, general and administrative

21,63523,531Other

50-Total costs and expenses

31,55129,624Loss from operations

(7,939)(21,620)Other income (expense), net

6,576(1,053)Net loss

$
(1,363)$
(22,673)Basic and diluted net loss per share

$
(0.02)$
(0.27)Shares used to compute basic anddiluted net loss per share

85,67285,519 CADENCE PHARMACEUTICALS, INC.CONDENSED BALANCE SHEETS(in thousands)March 31,December 31,20132012(unaudited)AssetsCurrent assets:Cash, cash equivalents and short-term investments 

$
4,240$
2,072Restricted cash 

640640Accounts receivable, net 

8,9086,152Inventory 

6,0836,498Prepaid expenses and other current assets 

2,0411,154Total current assets

81,91276,516Property and equipment, net

1,9051,967Intangible assets, net

11,75412,090Other assets

907,106Total assets

$
95,661$
97,679Liabilities and Stockholders' Equity Current liabilities:Accounts payable 

$
5,808$
5,796Accrued liabilities 

12,53212,969Deferred revenue 

-2,234Current debt, less discount 

2,552-Total current liabilities

20,89220,999Other liabilities

23351Long-term debt, less discount

26,38828,818Total stockholders' equity

48,14847,811Total liabilities and stockholders' equity

$
95,661
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2012 Financial Results
2. Cadence Pharmaceuticals To Present At The Deutsche Bank Securities, Inc. 37th Annual Health Care Conference In Boston On May 8, 2012
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
4. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
5. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
6. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
7. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
8. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
9. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
10. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
11. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... to manufacture proteins including biosimilar therapeutics, today announced that ... Annual NewsMakers in the Biotech Industry conference in ... chief executive officer of Pfenex, will provide an overview ... Friday, September 26, 2014 at 10:00 a.m. EDT/7:00 a.m. ...
(Date:9/19/2014)... September 19, 2014 ... http://www.researchandmarkets.com/research/b2jxhs/micro_market ) has announced the addition of the  ...  report to their offering.       (Logo: ... one of the fastest-growing segments in the chromatography ... in 2013, and expected to reach $2.0 billion ...
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... Mich. , Sept. 18, 2014  Health Enhancement Products, ... firm investigating early-stage algae bioactive compounds and metabolic processes, is ... the company,s board of directors. Ms. Nola E. Masterson ... investment advisor joined the board effective September 17, 2014. ... Masterson agree to join our board," states Andrew Dahl ...
Breaking Biology Technology:Pfenex to Present at Upcoming Industry Conference on September 26 2Micro Market Monitor : Global Pre-packed Chromatography Columns 2HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2
... could prove efficacious for both prophylactic and ... Corporation (NYSE AMEX: CVM ) ... that vaccines utilizing its proprietary L.E.A.P.S.(TM) (Ligand ... potentially induce protection against illnesses such as ...
... AKIVA, Israel, April 28 ITGI Medical, Ltd.,(TASE: ... and,marketing of heterologous tissue covered stents, announced that ... HUD (Humanitarian Use Device),designation to Over and Under(R) ... and dissections of native coronary arteries and,Saphenous Vein ...
... Inc. (NYSE Amex: PIP ), a biodefense ... announced today that results from a second Phase II ... Annual Conference on Vaccine Research, being held in Baltimore, ... the National Foundation of Infectious Diseases.David P. Wright, President ...
Cached Biology Technology:CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 2CEL-SCI's L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 2PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 3PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 4PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 5PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 6PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research 7
(Date:9/19/2014)... of Oklahoma biology professor will study the unique bioelectric ... could eventually benefit people,s health. The OU researcher ... energy required to produce the signals used to map ... signals at a rate of 500-600 discharges a second ... the electric fish are extreme, but necessary for survival. ...
(Date:9/19/2014)... , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... company focused on the growing m-commerce market, updates the "Wocket in ... in the lightweight and light middleweight weight classes, Vinny Pazienza ... was announced that Game of Thrones actor Ciaran ... with Children star Katey Sagal have been cast ...
(Date:9/18/2014)... sleep-promoting circuit located deep in the primitive brainstem has ... researchers at Harvard School of Medicine and the University ... is only the second "sleep node" identified in the ... and sufficient to produce deep sleep. , Published online ... demonstrates that fully half of all of the brain,s ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... , March 27, 2013  Definiens, the global leader of ... today announced it has appointed an Advisory Board comprising ... part of its market expansion strategy, Definiens established the ... opportunities in tissue diagnostics and clinical digital pathology. Members ...
... to prevent people with HIV from also becoming infected with ... State University. Behaviors that put people at higher risk ... getting blood transfusions, for instance also raise their risk ... liver and, if untreated, can be deadly. The study, ...
... (March. 27, 2013) A team of ... improve the neurobehavioral function of six week-old ... (ASCs) to treat hypoxic-ischemic brain injury, and found ... animals through exercise-induced fibroblast growth factor 2 (FGF2), ...
Cached Biology News:Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 2Gilde Healthcare III Portfolio Company Definiens Establishes Advisory Board 3HIV sufferers need hepatitis safeguards 2Environmental enrichment important factor impacting cell transplantation and brain repair 2Environmental enrichment important factor impacting cell transplantation and brain repair 3
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... Nop1p/Fibrillarin was originally identified ... yeast, Saccharomyces cerevisiae (accession P15646). The ... viability and is localized in the ... is fibrillarin (accession P22087) a component ...
Biology Products: